Comparative nigrostriatal dopaminergic imaging with iodine-123-βCIT- FP/SPECT and fluorine-18-FDOPA/PET

Journal of Nuclear Medicine

Volumn 37, Issue 11, 1996, Pages 1760-1765

  Ishikawa, Tatsuya ^b   Dhawan, Vijay ^b   Kazumata, Ken ^b   Chaly, Thomas ^b   Mandel, Francine ^b   Neumeyer, John ^b   Margouleff, Claude ^b   Babchyck, Barry ^b   Zanzi, Italo ^b   Eidelberg, David ^a  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^b NONE

Author keywords

dopamine transporter; Parkinson's disease; PET; SPECT

Indexed keywords

3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; COCAINE DERIVATIVE; DOPAMINE; FLUORINE 18; IODINE 123;

ADULT; AGED; AGING; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DISEASE SEVERITY; FEMALE; HUMAN; MALE; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; AGED; AGING; CARRIER PROTEINS; COCAINE; CORPUS STRIATUM; DIHYDROXYPHENYLALANINE; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; PARKINSON DISEASE; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 10344229443     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Brooks DJ. PET studies on the early and differential diagnosis of Parkinson's disease. Neurology 1993;43(suppl 6):S6-S16.
2. 18F-fluorodeoxyglucose and PET. Neurology 1995;45:1995-2004.
3. Takikawa S, Dhawan V, Chaly T, et al. Input functions for 6-[fluorine-8]fluorodopa quantitation in Parkinsonism: comparative studies and clinical correlations. J Nucl Med 1994;35:955-963.
4. Ishikawa T, Dhawan V, Chaly T, et al. The clinical significance of dopa decarboxylase activity in Parkinson's disease. J Nucl Med 1996;37:216-222.
5. 18F-fluorodopa positron emission tomography studies. Mov Disord 1990;5:203-213.
6. Innis RB, Seibyl JP, Scanley BE, et al. Single-photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson's disease. Proc Natl Acad Sci 1993;90:11965-11969.
7. 123I]βCIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 1993;13:295-309.
8. 123I]βCIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 1994;14:982-994.
9. Van Dyck CH, Seibyl JP, Malison RT, et al. Age-related decline in striatal dopamine transporter binding with iodine-123-βCIT SPECT. J Nucl Med 1995;36:1175-1181.
10. 123I]βCIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995;38:589-598.
11. Neumeyer JL, Wang S, Gao Y, et al. N-ω-fluoroalkyl analogs of (1R)-2β-carbomethyoxy-3β-(4-Iodophenyl)tropane (β-CIT): radiotracers for PET and SPECT imaging of dopamine transporters. J Med Chem 1994;37:1558-1561.
12. 123I]N-ω-fluoroalkyl-2β-carboxy-3β-(4-iodophenyl) nortropane esters in baboons. Nucl Med Biology 1995:211-219.
13. Abi-Dargham A, Gandelman M, DeErausquin G, et al. SPECT imaging of dopamine transporters in human brain with iodine-123 fluoroalkyl analogs of βCIT. J Nucl Med 1996;37:1129-1133.
14. Hoehn MM, Yahr MD. Parkinsonism: Onset, progression and mortality. Neurology 1967;17:21-25.
15. Fahn S, Elton RL, the UPDRS Development Committee. Unified Parkinson disease rating scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, eds. Recent developments in Parkinson's disease, vol. 2. Macmillan, Floral Park, New Jersey 1987:293-304.
16. DeGrado TR, Turkington TG, Williams JJ, et al. Performance characteristics of a whole-body PET scanner. J Nucl Med 1994;35:1398-1406.
17. Hariz MI, Erikson AT. Reproducibility of repeated mounting of a noninvasive CT/MRI stereoadapter. Appl Neurophysiol 1986;49:336-347.
18. 18F]fluoro-L-dopa for human studies with PET. Appl Radiat Isot 1990;41:275-281.
19. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983;3:1-7.
20. Resnick SM, Karp JS, Turetsky B, Gur RE. Comparison of anatomically-defined versus physiologcally-based regional localization: effects on PET-FDG quantitation. J Nucl Med 1993;34:2201-2207.
21. Anderson TW. An introduction to multivariate statistical analysis. New York: John Wiley and Sons: 1984.
22. 18F-Dopa uptake in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Ann Neurol 1990;28:547-555.
23. Sawle GV, Playford ED, Burn DJ, et al. Separating Parkinson's disease from normality. Arch Neurol 1994;51:237-243.
24. Dhawan V, Ishikawa T, Patlak C, et al. Combined FDOPA and 3OMFD PET studies in Parkinson's disease: modeling issues. J Nucl Med 1996;37:209-216.
25. Fearnley JM, Lees AJ. Aging. Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-2301.
26. Volkow ND, Fowler JS, Wang GJ, et al. Decreased dopamine transporters with age in healthy human subjects. Ann Neurol 1994;36:237-239.
27. Volkow ND, Ding YS, Fowler JS, et al. Dopamine transporters decrease with age in healthy subjects. J Nucl Med 1996;37:in press.
28. Murphy DGM, DeCarli C, Schapiro MB, et al. Age-related differences in volumes of subcortical nuclei, brain matter, and cerebrospinal fluid in healthy men as measured with magnetic resonance imaging. Arch Neurol 1992;49:839-845.
29. Martin WRW, Palmer MR, Patlak CS, et al. Nigrostriatal function in man studied with positron emission tomography. Ann Neurol 1989;26:535-542.
30. Vingerhoets FJG, Snow BJ, Schulzer M, et al. Reproducibility of fluorine-18-6-fluorodopa positron emission tomography in normal human subjects. J Nucl Med 1994;35:18-23.
31. Sawle GV, Colebatch JG, Shah A, Brooks DJ, Marsden CD, Frackowiak SJ. Striatal function in normal aging: implications for Parkinson's disease. Ann Neurol 1990;28: 799-804.
32. 18F-dopa uptake: absence of an aging effect. J Cereb Blood Flow Metab 1993;13:881-888.
33. Eidelberg D, Dhawan V, Moeller JR. An aging effect in striatal fluorodopa uptake? Large versus small ROIs. J Cereb Blood Flow Metab 1994;14:882-883.
34. Gjedde A, Reith J, Dyve S. Dopa decarboxylase activity of the living brain. Neurobiology 1991;88:2272-2725.
35. Kish SJ, Zhong XH, Hornykiewicz O, Haycock JW. Striatal DOPA decarboxylase in aging: disparity between postmortem and positron emission tomography studies? Ann Neurol 1995;38:260-264.
36. 11C-WIN 35, 428 reveals marked declines in mild Parkinson's disease. Ann Neurol 1993;34:423-431.
37. Schulzer M, Lee CS, Mak EK, Vingerhoets FJG, Calne DB. A mathematical model of pathogenesis in idiopathic parkinsonism. Brain 1994;117:509-516.